The award-winning BioCopy team covers both, business know-how and scientific expertise in various fields, such as biology, physics, manufacturing systems technology, assay development and microsystems technology. The expertise of the team headed by Dr. Günter Roth is complemented by renowned board members like Prof. Dr. Alexander van Gabain, Dr. Thomas Langer, Pascal Brenneisen and Rainer Boehm and advisors such as Dr. Markus Dürr.
Prof. Dr. Alexander van Gabain
Alexander von Gabain is a microbiologist, scientist, founder of several biotech companies and board member of venture capital companies. Throughout his career, he has worked at the interface of healthcare, science and research. As a co-founder of Intercell AG, he was able to register and market a novel vaccine against Japanese Encephalitis worldwide. Alexander von Gabain is CEO of INiTS, the Technology Seed Fund and Incubator of the University of Vienna and he is chairman of the board of the European Institute of Innovation and Technology (EIT). His commitment underlines the importance of BioCopy’s technology for the vaccine market.
Pascal Brenneisen has proven international expertise in the pharmaceutical, life science & IT industries, including general management, strategic business development, sales and marketing, operations and finance. In addition to his extensive functions at healthcare and pharmaceutical companies such as Novartis (President of Novartis Switzerland) and Sandoz (CEO UK & Ireland), he is a member of various boards of directors of start-up companies and SMEs (including Topadur Pharma AG, Konapharma Ltd. and IES AG). Pascal will drive the collaborations with key partners for the development and future marketing of BioCopy’s products and services.
Dr. Thomas Langer
Dr. Thomas Langer worked in private banking from 2005 to 2013, most recently as a member of the executive board at Wegelin & Co. Since 2013, he has been working as an independent entrepreneur in corporate restructuring (electronics) and since 2015 as an investor in selected start-ups (electronics, IoT, Biotech). He supports start-ups with his profound network, above all on the financing and sales side in the phase of company development. Dr. Thomas Langer is the owner of the electronics development company LTS AG, which covers the areas of traffic sensors and systemic energy management in the industrial sector.
Dr. Günter Roth
Dr. Günter Roth is the main inventor of the patents of the copying technology. Dr. Roth is a graduate physicist and graduate biochemist and has a comprehensive, interdisciplinary education. From 2008-2013 he was head of the group „Assay development “ at the chair of Prof. Dr. Zengerle and led the development of microfluidic systems and assays. He was involved in about 30 publications. During this time he developed the technique to copy biomolecules. From June 2013 to August 2018, he was head of a research group for the development of various applications of the biomolecule copy at the ZBSA (University of Freiburg).
Niko Bausch holds a BSc in Biochemistry, Genetics, Limnology and an MSc in Biology from the University of Freiburg (Germany), and an MBA from Edinburgh Business School. Thanks to his interdisciplinary knowledge in business & science, Niko has accumulated more than 10 years of experience in business development. He has worked in different biotech companies, thanks to which he has an in-depth know-how in various life science technologies and markets. His work experience includes: marketing and sales at Genolife SA, project manager at Metabolic Explorer, business developer at Charles River Discovery Research Services Germany GmbH and marketing manager at Genedata. Niko has also worked as a business developer and innovation manager at the Office for Technology Transfer at the University of Freiburg. There, he was initiator and project manager of the business plan competition „Startinsland“ and co-founder of the start-up BioCopy GmbH.
Rainer Boehm held several senior management positions from 1988 to 2017, including Head of the Novartis Cancer Business in North America (2005-2010), Chief Commercial & Medical Affairs Officer (2014-2016) and Interim CEO of Novartis Pharma AG (2016). He was a key figure in the successful establishment of Novartis Oncology. During his career he has launched and monitored many brands, including Femara, Zometa and Gleevec, as well as Cosentyx and Entresto. Today he is a board member of several life science companies such as Humanigen Inc., Cellectis SA and Nordic Nanovector ASA.
Dr. Markus Dürr
Dr. med. vet. Markus Dürr was a member of the Lucerne Cantonal Council from 1999 to 2009 and served as District President in 2003 and 2008. As a former Health Director of the Canton Lucerne and Chairman of the Board of Directors of the Swiss Accident Insurance (Suva), he has proven expertise in this field. As a doctor of veterinary medicine, he will support BioCopy in the planning of animal experiments and the development of the first vaccine.